+Undoctored
Media release from The Lancet
Friday 16 July 2021, 12:02 PM
8 minutes to Read
• Study is most comprehensive of its kind and included more than 70,000 adults in the UK hospitalised with severe COVID-19 disease. Of these, half (36,367 of 73,197) developed one or more health complication during their hospitalisation.
• Most common complications included renal, complex respiratory, and systemic complications, but cardiovascular, neurological, and gastrointestinal and liver complications were also reported.
• The study found high rates of complications across all age groups. Men and those aged older than 60 years were most likely affected, but complications and poor functional outcomes were common, even in younger, previously healthy adults.
Kids Get Long COVID Too - Scientific American
scientificamerican.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scientificamerican.com Daily Mail and Mail on Sunday newspapers.
Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2 × 2 factorial, randomised controlled trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Patients on Methotrexate Show T-Cell Response to Pfizer Vaccine
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Getty Images for Empire State Re
Monica Schipper/Getty Images
A healthcare worker administers the vaccine as the Empire State Building offers Covid-19 vaccines at its observatory on June 18
By Jacqueline Howard, CNN
Vaccine makers are preparing for a next possible phase of the Covid-19 vaccine rollout: booster doses.
The biopharmaceutical company Pfizer announced on Thursday that it has seen waning immunity from its coronavirus vaccine although efficacy in preventing serious illness remains high but did not detail the evidence. It said a third dose may be needed six to 12 months after full vaccination.
The company said it would publish “more definitive data soon” and in August would seek emergency use authorization from the US Food and Drug Administration for a booster dose.